Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760334 | 0.80 | JAK3 (0.39) | POLBKDM4EGAAALDH1A1JAK1 | |
| SCHEMBL27696590 | 0.77 | P4HTM (0.40) | NPC1RAB9APOLBKDM4EMEN1 | |
| SCHEMBL13341001 | 0.74 | HTT (0.50) | MEN1KMT2AP4HTMALDH1A1HPGD | |
| SCHEMBL4759408 | 0.73 | MCHR1 (0.38) | NPC1RAB9AP4HTMALDH1A1MAPT | |
| SCHEMBL4758882 | 0.71 | JAK2 (0.41) | NPC1RAB9AP4HTMALDH1A1JAK1 | |
| SCHEMBL1845562 | 0.69 | MAPT (0.48) | NPC1RAB9APOLBKDM4EMEN1 | |
| SCHEMBL1845515 | 0.67 | NPC1 (0.51) | NPC1RAB9APOLBKDM4EMEN1 | |
| SCHEMBL12695029 | 0.66 | RRM2 (0.46) | KDM4EALDH1A1MAPT | |
| SCHEMBL20037649 | 0.65 | MAPT (0.35) | GAAMAPT | |
| SCHEMBL14283236 | 0.63 | RRM2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194640-A1 | Optically Active Tetrahydronaphthalene Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-14 | — | — | US | claimed |
| CN-101119986-A | Optically active tetrahydronaphthalene derivative | MITSUBISHI PHARMA CORP (JP) | 2008-02-06 | — | — | CN | claimed |
| EP-1852431-A1 | OPTICALLY ACTIVE TETRAHYDRONAPHTHALENE DERIVATIVE | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-07 | — | — | EP | claimed |
| CN-101119986-B | Optically active tetrahydronaphthalene derivative | MITSUBISHI PHARMA CORP | 2011-07-06 | — | — | CN | disclosed |
| US-20080194640-A1 | Optically Active Tetrahydronaphthalene Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080194640-A1 | Optically Active Tetrahydronaphthalene Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| CN-101119986-A | Optically active tetrahydronaphthalene derivative | MITSUBISHI PHARMA CORP (JP) | 2008-02-06 | — | — | CN | disclosed |
| EP-1852431-A1 | OPTICALLY ACTIVE TETRAHYDRONAPHTHALENE DERIVATIVE | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194640-A1 | Optically Active Tetrahydronaphthalene Derivative | C3AR1, C5AR1, C5AR2 | NPC1 1787/4885RAB9A 1564/4885POLB 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.